Skip to main content
SpringerLink
Log in

Treatment with Antiobesity Drugs in Weight Regain After Bariatric Surgery: a Retrospective Cohort Study

  • Brief Communication
  • Published:
Obesity Surgery Aims and scope Submit manuscript

Abstract

Background

Bariatric surgery is the most efficient treatment for obesity. However, in some cases, weight regain can occur. Currently, it is unknown the best antiobesity medication (AOM) for such clinical situation. This study aims to evaluate the effect of AOM in patients with weight regain after bariatric surgery.

Methods

A retrospective cohort study from December 2010 to July 2019 with patients submitted to bariatric surgery that had weight regain and received AOM for at least 2 years.

Results

Of 96 patients that had weight regain in the analyzed period and received AOM, 16 were excluded from the analysis due to non-compliance (n = 7), treatment failure (n = 5), intolerable side effects with all available AOM (n = 2), or interaction with other medications (n = 2). Eighty patients were included in the analysis. The mean age was 59.0 ± 10.1 years, 88.8% were female, 91.2% white, and most of them were submitted to gastric bypass (87.6%). The mean preoperative and nadir weight after surgery were 127.9 ± 25.5 kg and 84.7 ± 22.8 kg, respectively. At the initiation of AOM, the mean baseline weight was 99.4 ± 23.1 kg. After 2 years of follow-up, there was significant weight loss in the groups treated with topiramate-alone (− 3.2 kg), topiramate plus sibutramine (− 6.1kg), and orlistat-alone or in combination (− 3.9kg). No statistical difference was observed in the sibutramine-alone group.

Conclusion

Topiramate (alone or associated with sibutramine) and orlistat (alone or in combination) promoted significant weight loss after 2 years of use in patients submitted to bariatric surgery with weight regain.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cooper TC, Simmons EB, Webb K, et al. Trends in weight regain following Roux-en-Y gastric bypass (RYGB) bariatric surgery. Obes Surg. 2015;25:1474–81.

    Article  PubMed  Google Scholar 

  2. Lucas E, Simmons O, Tchang B, et al. Pharmacologic management of weight regain following bariatric surgery. Front Endocrinol. 2023;13:1043595.

    Article  Google Scholar 

  3. Noria SF, Shelby RD, Atkins KD, et al. Weight regain after bariatric surgery: scope of the problem, causes, prevention, and treatment. Curr Diab Rep. 2023;23:31–42.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Brown CS, Rabinstein AA, Nystrom EM, et al. Antiseizure medication use in gastric bypass patients and other post-surgical malabsorptive states. Epilepsy Behav Rep. 2021;16:100439.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Jensen AB, Renström F, Aczél S, et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023;33:1017–25.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Murvelashvili N, Xie L, Schellinger JN, et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obes. 2023;31:1280–9.

    Article  CAS  Google Scholar 

  7. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.

    Article  PubMed  Google Scholar 

  8. Halpern B, Mancini MC, de Melo ME, et al. Proposal of an obesity classification based on weight history: an official document by the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society for the Study of Obesity and Metabolic Syndrome (ABESO). Arch Endocrinol Metab. 2022;66:139–51.

    PubMed  PubMed Central  Google Scholar 

  9. Edgerton C, Mehta M, Mou D, et al. Patterns of weight loss medication utilization and outcomes following bariatric surgery. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2021;25:369–77.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unidade de Obesidade, Disciplina de Endocrinologia e Metabologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo, SP, 05403-010, Brazil

    Bibiana S. Boger, Nara L. Queiroz, Paulo E. P. Noriega, Maicon C. Canuto, Matheo A. M. Stumpf, Cintia Cercato, Marcio C. Mancini & Maria E. de Melo

Authors
  1. Bibiana S. Boger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nara L. Queiroz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paulo E. P. Noriega
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maicon C. Canuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matheo A. M. Stumpf
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cintia Cercato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marcio C. Mancini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria E. de Melo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matheo A. M. Stumpf.

Ethics declarations

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

For this type of retrospective study, informed consent does not apply.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Key Points

− Weigh regain can occur in almost one-third of patients submitted to bariatric surgery

− Few studies evaluated this population and is unclear which should be the drug of choice for treatment

− In the present study, the combination of topiramate plus sibutramine had the most significant potency for weight loss (− 6.1 kg, 5.9%)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boger, B.S., Queiroz, N.L., Noriega, P.E.P. et al. Treatment with Antiobesity Drugs in Weight Regain After Bariatric Surgery: a Retrospective Cohort Study. OBES SURG 33, 2941–2944 (2023). https://doi.org/10.1007/s11695-023-06736-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11695-023-06736-7

Keywords

Search

Navigation